<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The <z:chebi fb="0" ids="10119">Ziprasidone</z:chebi> Observational study of car DIAC Outcomes (ZODIAC), a large simple trial comparing <z:chebi fb="0" ids="10119">ziprasidone</z:chebi> versus <z:chebi fb="0" ids="7735">olanzapine</z:chebi> in real-world use, showed no difference in risk of <z:hpo ids='HP_0001699'>sudden death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Upon the request of the US Food and Drug Administration, 205 fatal events were readjudicated applying <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-10 coding rules for <z:hpo ids='HP_0001699'>sudden death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A readjudication committee coded three domains (witness to <z:hpo ids='HP_0011420'>death</z:hpo>, time of symptom <z:hpo ids='HP_0003674'>onset</z:hpo> to <z:hpo ids='HP_0011420'>death</z:hpo>, and most likely cause of <z:hpo ids='HP_0011420'>death</z:hpo>) for use within algorithms consistent with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-10 rules </plain></SENT>
<SENT sid="3" pm="."><plain>Relative risks (RR) and corresponding 95%CI were calculated for persons randomized to <z:chebi fb="0" ids="10119">ziprasidone</z:chebi> versus <z:chebi fb="0" ids="7735">olanzapine</z:chebi>, comparing 1-year incidence of <z:hpo ids='HP_0001699'>sudden death</z:hpo>, using multiple definitions </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Data on symptom <z:hpo ids='HP_0003674'>onset</z:hpo> to <z:hpo ids='HP_0011420'>death</z:hpo> and diagnosis of specific <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> required by the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-10 rules were often lacking </plain></SENT>
<SENT sid="5" pm="."><plain>Sensitivity analyses were conducted to explore the impact of cases suggestive of cardiac origin but missing data required by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-10 <z:hpo ids='HP_0001699'>sudden death</z:hpo> codes </plain></SENT>
<SENT sid="6" pm="."><plain>Overall, the readjudicated data matched the study's initial findings, with no significant difference in 1-year mortality between <z:chebi fb="0" ids="10119">ziprasidone</z:chebi> and <z:chebi fb="0" ids="7735">olanzapine</z:chebi> for <z:hpo ids='HP_0001699'>sudden death</z:hpo> not otherwise specified and <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> (R96.0 or R96.1 or I46.1; RR = 1.11, 95%CI 0.45- 2.77) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: After outcome readjudication, ZODIAC found no difference in the risk of <z:hpo ids='HP_0001699'>sudden death</z:hpo> among those randomized to <z:chebi fb="0" ids="10119">ziprasidone</z:chebi> versus <z:chebi fb="0" ids="7735">olanzapine</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>However, unlike hospital-based studies, fatal events in general population studies often occur outside hospital and often lack the clinical detail needed for the exact determination of symptom <z:hpo ids='HP_0003674'>onset</z:hpo> and event </plain></SENT>
<SENT sid="9" pm="."><plain>Epidemiological evaluations of <z:hpo ids='HP_0001699'>sudden death</z:hpo> need to consider the limitations of the available data </plain></SENT>
</text></document>